Search research articles
Contact Us
Filters
Showing results (51-60 of 107) with videos related to
Page
of 11
Sort By:
Leukemia
|
May 24, 2019
A revised international prognostic score system for Waldenström's macroglobulinemia
Efstathios Kastritis, Pierre Morel, Alain Duhamel, et al.
British Journal of Haematology
|
July 16, 2013
Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups
Jean-Christophe Ianotto, Françoise Boyer-Perrard, Emmanuel Gyan, et al.
Haematologica
|
December 9, 2017
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, et al.
Blood
|
August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Blood
|
November 18, 2023
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients
Hervé Ghesquières, Daphné Krzisch, Emmanuelle Nicolas-Virelizier, et al.
Haematologica
|
February 9, 2019
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
Marie Sébert, Aline Renneville, Cécile Bally, et al.
Blood Advances
|
August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
Constantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.
Blood
|
August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
Eunice S Wang, Pau Montesinos, Mark D Minden, et al.
Blood
|
March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
Blood Cancer Journal
|
October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 107) with videos related to
Sort By:
Page
of 11
Leukemia
|
May 24, 2019
A revised international prognostic score system for Waldenström's macroglobulinemia
Efstathios Kastritis, Pierre Morel, Alain Duhamel, et al.
British Journal of Haematology
|
July 16, 2013
Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups
Jean-Christophe Ianotto, Françoise Boyer-Perrard, Emmanuel Gyan, et al.
Haematologica
|
December 9, 2017
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, et al.
Blood
|
August 11, 2011
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Thorsten Braun, Raphael Itzykson, Aline Renneville, et al.
Blood
|
November 18, 2023
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients
Hervé Ghesquières, Daphné Krzisch, Emmanuelle Nicolas-Virelizier, et al.
Haematologica
|
February 9, 2019
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure
Marie Sébert, Aline Renneville, Cécile Bally, et al.
Blood Advances
|
August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies
Constantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.
Blood
|
August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
Eunice S Wang, Pau Montesinos, Mark D Minden, et al.
Blood
|
March 29, 2020
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H Wei, Pau Montesinos, Vladimir Ivanov, et al.
Blood Cancer Journal
|
October 2, 2021
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Page
of 11